Quest Diagnostics (DGX)
NYSE:DGX
Want to see DGX full AI Analyst Report?
DGX Stock Chart & Stats
$195.02
-$0.03(-0.02%)
At close: 4:00 PM EST
$195.02
-$0.03(-0.02%)
Day’s Range― - ―
52-Week Range$164.65 - $213.50
Previous CloseN/A
Volume143.08K
Average Volume (3M)810.83K
Market Cap
$21.59B
Enterprise Value$28.48B
Total Cash (Recent Filing)$393.00M
Total Debt (Recent Filing)$6.98B
Price to Earnings (P/E)20.9
Beta0.10
Next Earnings
Jul 23, 2026EPS Estimate
2.82Next Dividend Ex-DateN/A
Dividend Yield1.8%
Share Statistics
EPS (TTM)9.17
Shares Outstanding110,696,430
10 Day Avg. Volume867,008
30 Day Avg. Volume810,834
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)2.69
Price to Sales (P/S)1.75
P/FCF Ratio14.17
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue2.53
Enterprise Value/Gross Profit7.60
Enterprise Value/Ebitda13.41
Forecast
1Y Price Target
$223.13Price Target Upside14.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)10.75
Revenue Forecast (FY)$11.86B
Bulls Say, Bears Say
Bulls Say
National Scale And Diversified Customer BaseA nationwide lab network and broad customer mix (physicians, hospitals, plans, employers, consumers) provide durable scale advantages: lower unit costs, bargaining leverage with payers, and multiple revenue channels that stabilize volumes across local demand cycles and support long-term margin resilience.
Sustained Revenue And Volume Growth With Raised GuidanceDouble-digit requisition and organic revenue growth, plus a guidance raise, indicate durable demand recovery and execution. Embedded contributions from large collaborations and core volume growth provide predictable top-line momentum that supports capacity planning and multi-quarter visibility into revenue and margin trajectory.
Advanced Diagnostics Outperformance And Capacity InvestmentStrong growth in molecular/genetic and specialty tests drives higher per-test pricing and better margins. Management’s targeted capex to expand esoteric lab capacity is structural: scaling these higher-margin services supports sustained margin expansion and revenue mix improvement over the medium term.
Bears Say
Meaningful Leverage Despite ImprovementDebt near parity with equity constrains financial flexibility for larger M&A, faster share repurchases, or step-up investments. Although leverage has improved from earlier levels, the still-meaningful debt load increases sensitivity to cash flow volatility and limits the firm’s ability to pursue opportunistic strategic moves without raising additional capital.
Weaker Cash Conversion And Slightly Negative FCF MomentumConsistent positive FCF is a strength, but conversion below earnings and slight negative FCF growth reduce the margin for funding capex, Project Nova investments, or elevated working capital needs. Weaker cash conversion increases reliance on debt markets for large discretionary uses and heightens sensitivity to timing swings in receivables/payables.
Mix Pressure From Large Collaborations Reducing Revenue Per RequisitionLarge partnership ramps materially boost volume but skew mix toward routine, lower-priced tests, pressuring revenue per requisition and near-term margins. Until esoteric capacity and higher-margin offerings scale, these structural mix effects can restrain per-unit economics despite rising aggregate volumes.
Quest Diagnostics News
DGX FAQ
What was Quest Diagnostics’s price range in the past 12 months?
Quest Diagnostics lowest stock price was $164.65 and its highest was $213.50 in the past 12 months.
What is Quest Diagnostics’s market cap?
Quest Diagnostics’s market cap is $21.59B.
When is Quest Diagnostics’s upcoming earnings report date?
Quest Diagnostics’s upcoming earnings report date is Jul 23, 2026 which is in 32 days.
How were Quest Diagnostics’s earnings last quarter?
Quest Diagnostics released its earnings results on Apr 21, 2026. The company reported $2.5 earnings per share for the quarter, beating the consensus estimate of $2.366 by $0.134.
Is Quest Diagnostics overvalued?
According to Wall Street analysts Quest Diagnostics’s price is currently Undervalued.
Does Quest Diagnostics pay dividends?
Quest Diagnostics pays a Quarterly dividend of $0.86 which represents an annual dividend yield of 1.8%. See more information on Quest Diagnostics dividends here
What is Quest Diagnostics’s EPS estimate?
Quest Diagnostics’s EPS estimate is 2.82.
How many shares outstanding does Quest Diagnostics have?
Quest Diagnostics has 110,696,430 shares outstanding.
What happened to Quest Diagnostics’s price movement after its last earnings report?
Quest Diagnostics reported an EPS of $2.5 in its last earnings report, beating expectations of $2.366. Following the earnings report the stock price went up 4.447%.
Which hedge fund is a major shareholder of Quest Diagnostics?
Currently, no hedge funds are holding shares in DGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quest Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$223.13 (14.41% Upside)
$223.13 (14.41% Upside)
Blogger Sentiment
Bullish
DGX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 798.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.42%
12-Months-Change
Fundamentals
Return on Equity
14.11%
Trailing 12-Months
Asset Growth
5.55%
Trailing 12-Months
Company Description
Quest Diagnostics
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
DGX Company Deck
DGX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported broadly strong commercial and operational performance: double-digit volume growth, ~9% organic revenue growth, margin expansion on an adjusted basis, AI/automation-driven productivity gains, and raised full‑year guidance. Near-term headwinds include mix-driven revenue-per-requisition pressure from large collaboration ramps, lower Q1 cash flow, wage/weather/fuel cost impacts, Project Nova investment dilution, and ongoing regulatory/Medicare rate uncertainty. Overall, the positives (revenue/volume growth, EPS improvement, strategic partnerships and productivity gains) outweigh the described challenges.View all DGX earnings summariesDGX Revenue Breakdown
97.73% Diagnostic Information Services
2.27% DS businesses
DGX Stock 12 Month Forecast
Average Price Target
$223.13
▲(14.41% Upside)
Technical Analysis
Ownership Overview
0.46% Insiders
28.96% Mutual Funds
17.39% Other Institutional Investors
24.04% Public Companies and
Individual Investors